<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512459785</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512459785</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Jin-Ye</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459785">1</xref>
<xref ref-type="aff" rid="aff2-1352458512459785">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Kai</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459785">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Xian-Wen</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459785">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Jian-Wen</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512459785">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Kan</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512459785">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Ming-Wei</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512459785">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Luo</surname><given-names>Ben-Yan</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512459785">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512459785"><label>1</label>Department of Neurology, the First Affiliated Hospital of Anhui Medical University, China</aff>
<aff id="aff2-1352458512459785"><label>2</label>Brain Medical Center and Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, China</aff>
<author-notes>
<corresp id="corresp1-1352458512459785">Ben-Yan Luo, Brain Medical Center and Department of Neurology the First Affiliated Hospital, Zhejiang University School of Medicine, 89 Qingchun Road, Hangzhou 310003, China. Email: <email>luobenyan@zju.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>5</issue>
<fpage>639</fpage>
<lpage>643</lpage>
<history>
<date date-type="received">
<day>4</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>7</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>1</day>
<month>8</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Two patients presented with initial symptoms of headache and fever, and two weeks later had disturbance of consciousness. Cerebrospinal fluid (CSF) showed pleocytosis &gt;500×10<sup>6</sup>/L. Magnetic resonance imaging (MRI) showed multiple brain lesions at sites of high aquaporin-4 (AQP-4) expression. Case 1 presented optic neuritis four years after the first attack and case 2 had symptoms of myelitis three weeks after headache. Serum AQP-4 antibody was positive in both cases, and the diagnosis of neuromyelitis optica spectrum disorder (NMOSD) was made. Accordingly, NMOSD can initially present as meningoencephalitis mimicking intracranial infection, and the characteristic MRI imaging is quite critical for differentiation.</p>
</abstract>
<kwd-group>
<kwd>AQP-4 antibody</kwd>
<kwd>brain lesions</kwd>
<kwd>meningoencephalitis</kwd>
<kwd>myelitis</kwd>
<kwd>NMO spectrum disorder</kwd>
<kwd>optic neuritis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512459785" sec-type="intro">
<title>Introduction</title>
<p>Meningoencephalitis may be caused by infective or non-infective factors, and the former are more common. The clinical treatments are completely different for each cause, so correct differential diagnosis at an early stage is extremely important for management decisions and prognosis. Here, we report fairly rare cases of neuromyelitis optica spectrum disorder (NMOSD), in which the patients initially presented with headache and high pleocytosis in the cerebrospinal fluid (CSF) resembling intracranial infection, but were finally diagnosed as having NMOSD.</p>
</sec>
<sec id="section2-1352458512459785">
<title>Cases</title>
<sec id="section3-1352458512459785">
<title>Case 1</title>
<p>A 40-year-old man complained of the initial symptom of headache in 2006. Fifteen days later, he had symptoms of meningoencephalitis (headache, 40°C fever and disturbance of consciousness) with positive Kernig’s sign, nuchal rigidity and bilateral Babinski sign. Magnetic resonance imaging (MRI) showed multiple T<sub>2</sub>WI hyperintense lesions in the right periventricular regions, corpus callosum, hypothalamus, cerebral peduncle, midbrain and upper pons. Contrast-enhanced MRI showed irregular parenchymal and meningeal gadolinium enhancement (<xref ref-type="fig" rid="fig1-1352458512459785">Figure 1A</xref>). Lumbar puncture showed intracranial hypertension of 310 mmH<sub>2</sub>O, CSF protein 102 mg/dL, white blood cell count 606×10<sup>6</sup>/L (lymphocytes accounted for 95%) and red blood cells 20×10<sup>6</sup>/L, with normal glucose and chloride levels. All indicators of bacteria and viruses were negative. All immunologic indicators were normal. A diagnosis of suspected tuberculous meningoencephalitis was established and anti-tuberculosis treatment with 10 mg dexamethasone was given. Three days later, his symptoms of headache and disturbed consciousness, and the CSF indictors, improved markedly. He was discharged without any symptoms.</p>
<fig id="fig1-1352458512459785" position="float">
<label>Figure 1.</label>
<caption>
<p><bold>Brain magnetic resonance imaging (MRI) in case 1</bold>. Serial MRI images showing lesions from the first (A), second (B) and third attack (C). (A) Upper panels: in 2006, MRI showed T2 hyperintense lesions in the right periventricular regions of parietal, occipital and temporal lobes, corpus callosum, hypothalamus and cerebral peduncle; lower panels: 12 days later, lesions extended to the midbrain and upper pons, with irregular parenchymal and meningeal gadolinium enhancement (images in the white box). (B) Three years later, MRI showed T<sub>2</sub> hyperintense lesions in the right periventricular region and corpus callosum, bilateral hypothalamus, cerebral peduncle and midbrain. (C) Two months after the second attack, T<sub>2</sub> hyperintense lesions extended to the right pons.</p>
</caption>
<graphic xlink:href="10.1177_1352458512459785-fig1.tif"/>
</fig>
<p>Three years later, he had worsened with diplopia and mild ptosis in the left eye, associated with numbness in the right face, an unstable gait and a bilateral positive Babinski sign. MRI showed multiple T<sub>2</sub> hyperintense lesions in the right periventricular region and corpus callosum, bilateral hypothalamus, cerebral peduncle and midbrain without gadolinium enhancement (<xref ref-type="fig" rid="fig1-1352458512459785">Figure 1B</xref>). Lumbar puncture showed CSF protein 66 mg/dL, with normal pressure and cell counts. His symptoms relieved after methylprednisolone treatment.</p>
<p>Two months after the second attack, he presented with numbness on the left side and weakness in the left leg. Muscle strength was grade four out of five in the left leg and five out of five in the other three limbs. MRI showed lesions extending to the right pons without gadolinium enhancement (<xref ref-type="fig" rid="fig1-1352458512459785">Figure 1C</xref>). The intracranial pressure, cell counts and CSF protein were normal. Again, his symptoms disappeared with methylprednisolone treatment. Before discharge, azathioprine tablets were added.</p>
<p>The recurrent brain lesions were typical of NMO,<sup><xref ref-type="bibr" rid="bibr1-1352458512459785">1</xref></sup> and his symptoms were highly responsive to steroids, which reminded us of NMOSD. After the third discharge, serum aquaporin-4 (AQP-4) antibody was tested by enzyme-linked immunosorbent assay<sup><xref ref-type="bibr" rid="bibr2-1352458512459785">2</xref></sup> and showed positive.</p>
<p>He went back to work and then withdrew from prednisone and azathioprine one year later on his own. Six months after withdrawal (in 2011), he presented with visual loss and color blindness (red and green) in the left eye but was normal in the right eye. Visual-evoked potentials were severely abnormal on the left and mildly abnormal on the right. Again, the visual loss was relieved with methylprednisolone and azathioprine treatment. Now, this case fulfilled the diagnostic criteria of NMOSD proposed in 2007.<sup><xref ref-type="bibr" rid="bibr3-1352458512459785">3</xref></sup></p>
</sec>
<sec id="section4-1352458512459785">
<title>Case 2</title>
<p>A 38-year-old woman complained of headache at first. Two weeks later she had symptoms of dizziness, nausea, vomiting, excessive daytime sleepiness, apathy and a 37.9°C fever, with positive Kernig’s sign and nuchal rigidity, horizontal nystagmus in the right position and negative pyramidal signs. MRI showed multiple T2WI hyperintense lesions around the third ventricle, in the corpus callosum, bilateral periventricular parenchyma, temporal lobes, thalamus, cerebellum and cerebellar peduncle (<xref ref-type="fig" rid="fig2-1352458512459785">Figure 2l</xref> and <xref ref-type="fig" rid="fig2-1352458512459785">m</xref>). Contrast-enhanced MRI showed irregular parenchymal, meningeal and bilateral ependymal gadolinium enhancement (<xref ref-type="fig" rid="fig3-1352458512459785">Figure 3g</xref> and <xref ref-type="fig" rid="fig3-1352458512459785">h</xref>). Lumbar puncture showed intracranial hypertension of 200 mmH<sub>2</sub>O, CSF protein 285 mg/dL, white blood cell count 625×10<sup>6</sup>/L and neutrophils 218×10<sup>6</sup>/L (monocytes accounted for 65.1%), with lower glucose (1.68 mmol/L; blood sugar 5.13 mmol/L) and normal chloride levels. The erythrocyte sedimentation rate was 34 mm/h, and all immunologic indicators were normal. A diagnosis of suspected tuberculous meningoencephalitis was established and anti-tuberculosis treatment with 10 mg dexamethasone was given. Ten days later, she had symptoms of light coma, horizontal and vertical nystagmus, muscle strength was grade one out of five in all limbs, and the Babinski sign was positive bilaterally. A second MRI showed the brain lesions were little changed (<xref ref-type="fig" rid="fig2-1352458512459785">Figure 2a</xref>–<xref ref-type="fig" rid="fig2-1352458512459785">k</xref>), whereas gadolinium enhancement was more distinct (<xref ref-type="fig" rid="fig3-1352458512459785">Figure 3a</xref>–<xref ref-type="fig" rid="fig3-1352458512459785">f</xref>, <xref ref-type="fig" rid="fig3-1352458512459785">i</xref>–<xref ref-type="fig" rid="fig3-1352458512459785">l</xref>), and cervical spinal MRI showed longitudinally extensive lesions (<xref ref-type="fig" rid="fig4-1352458512459785">Figure 4a</xref>–<xref ref-type="fig" rid="fig4-1352458512459785">f</xref>). The MRI lesions were localized at sites of high AQP-4 expression, and the “cloud-like enhancement” (<xref ref-type="fig" rid="fig3-1352458512459785">Figure 3a</xref> and <xref ref-type="fig" rid="fig3-1352458512459785">d</xref>)<sup><xref ref-type="bibr" rid="bibr4-1352458512459785">4</xref></sup> and “pencil-thin” ventricular ependymal enhancement (<xref ref-type="fig" rid="fig3-1352458512459785">Figure 3b</xref> and <xref ref-type="fig" rid="fig3-1352458512459785">c</xref>)<sup><xref ref-type="bibr" rid="bibr5-1352458512459785">5</xref></sup> were quite characteristic of NMO. The serum T-SPOT.TB test was negative and AQP-4 antibody (transfected cell-based assay)<sup><xref ref-type="bibr" rid="bibr2-1352458512459785">2</xref></sup> was positive. Accordingly, a diagnosis of NMOSD was established and she was treated with 1000 mg methylprednisolone per day. Three days later, her symptoms of disturbed consciousness and muscle strength improved markedly. Ten days later, lumbar puncture showed CSF protein 61 mg/dL, white blood cell count 38×10<sup>6</sup>/L (monocytes accounted for 100%), with normal glucose and chloride levels. One month after methylprednisolone treatment, MRI showed the brain and upper cervical spinal cord lesions were little changed (imaging not shown), while the lower cervical spinal cord lesions had disappeared (<xref ref-type="fig" rid="fig4-1352458512459785">Figure 4</xref>, <xref ref-type="fig" rid="fig4-1352458512459785">g</xref> and <xref ref-type="fig" rid="fig4-1352458512459785">h</xref>) and the enhancement improved greatly (<xref ref-type="fig" rid="fig3-1352458512459785">Figure 3m</xref>–<xref ref-type="fig" rid="fig3-1352458512459785">p</xref>). Then, anti-tuberculosis drugs were withdrawn and azathioprine was added. Two months after methylprednisolone treatment, all the symptoms and signs disappeared except for mild weakness, while only a small part of the T2WI hyperintense lesions disappeared (imaging not shown).</p>
<fig id="fig2-1352458512459785" position="float">
<label>Figure 2.</label>
<caption>
<p><bold>Brain magnetic resonance imaging (MRI) in case 2</bold>. MRI showed T<sub>2</sub> hyperintense lesions in the bilateral periventricular parenchyma, corpus callosum, around the third ventricle, temporal lobes, thalamus, brainstem, cerebellum and cerebellar peduncle.</p>
</caption>
<graphic xlink:href="10.1177_1352458512459785-fig2.tif"/>
</fig>
<fig id="fig3-1352458512459785" position="float">
<label>Figure 3.</label>
<caption>
<p><bold>Contrast-enhanced magnetic resonance imaging (MRI) in case 2</bold>. Contrast-enhanced MRI (a–l) showed gadolinium enhancement of bilateral periventricular parenchyma (cloud-like enhancement in a and d), meninges and bilateral ependyma (pencil-thin enhancement in b and c), brainstem, cerebellum and upper cervical spinal cord (i and k). The enhancement of periventricular parenchyma, meninges, ependyma, brainstem, cerebellum and upper cervical spinal cord improved greatly after methylprednisolone treatment (m–p).</p>
</caption>
<graphic xlink:href="10.1177_1352458512459785-fig3.tif"/>
</fig>
<fig id="fig4-1352458512459785" position="float">
<label>Figure 4.</label>
<caption>
<p><bold>Cervical spinal cord magnetic resonance imaging (MRI) imaging in case 2</bold>. MRI showed longitudinally extensive T<sub>2</sub> hyperintense lesions in medulla oblongata and cervical spinal cord (a–f). The T<sub>2</sub> hyperintense lesions of lower cervical spinal cord disappeared and upper cervical spinal cord improved after methylprednisolone treatment (g and h).</p>
</caption>
<graphic xlink:href="10.1177_1352458512459785-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section5-1352458512459785" sec-type="discussion">
<title>Discussion</title>
<p>The findings on anti-AQP4 antibody and its target antigen, AQP-4, have led to further understanding of NMO and NMOSD.<sup><xref ref-type="bibr" rid="bibr6-1352458512459785">6</xref></sup> Recently, the spectrum of clinical manifestations associated with AQP4 antibody has become broader.<sup><xref ref-type="bibr" rid="bibr7-1352458512459785">7</xref></sup> Brain abnormalities are observed in up to 75%,<sup><xref ref-type="bibr" rid="bibr8-1352458512459785">8</xref></sup> and central nervous system (CNS) symptoms occur in 45% of AQP4-seropositive patients.<sup><xref ref-type="bibr" rid="bibr9-1352458512459785">9</xref></sup> Furthermore, reports of brain involvement as an initial manifestation of NMOSD have been on the increase in recent years.<sup><xref ref-type="bibr" rid="bibr7-1352458512459785">7</xref>,<xref ref-type="bibr" rid="bibr10-1352458512459785">10</xref></sup> Periventricular tissue, hypothalamus, corpus callosum and brainstem are the most vulnerable regions in NMO and NMOSD.<sup><xref ref-type="bibr" rid="bibr1-1352458512459785">1</xref>,<xref ref-type="bibr" rid="bibr8-1352458512459785">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458512459785">9</xref>,<xref ref-type="bibr" rid="bibr11-1352458512459785">11</xref></sup> Atypical presentations of NMO, such as intractable hiccups, nausea and vomiting, as well as sleepiness, have been reported.<sup><xref ref-type="bibr" rid="bibr12-1352458512459785">12</xref></sup> However, headache with fever, meningeal irritation and prominent leukocytosis in the CSF mimicking intracranial infection as the initial presentation of NMOSD has not been reported.</p>
<p>In our cases, 606×10<sup>6</sup>/L and 625×10<sup>6</sup>/L white blood cells were found in the CSF, which resembled CNS infection. It has been reported that the CSF findings of NMO change greatly and are not easy to differentiate from cerebral infection: The cell count is &gt;50×10<sup>6</sup>/L in 13–35% of patients and up to 1000×10<sup>6</sup>/L in a few cases.<sup><xref ref-type="bibr" rid="bibr13-1352458512459785">13</xref></sup> Though symptoms and CSF findings change greatly in NMO and NMOSD, the brain lesion distribution at sites of high AQP-4 expression is the characteristic MRI manifestation.<sup><xref ref-type="bibr" rid="bibr2-1352458512459785">2</xref>,<xref ref-type="bibr" rid="bibr8-1352458512459785">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458512459785">9</xref>,<xref ref-type="bibr" rid="bibr11-1352458512459785">11</xref></sup> NMOSD was a possible diagnosis at this stage in the two cases, but did not fulfill the current diagnostic criteria of NMO. In any case, treatment with steroids and immunosuppression is the same for NMOSD and NMO. Case 1 fully recovered only with 10 mg dexamethasone, while case 2 continued to worsen with 10 mg dexamethasone, was relieved after 1000 mg methylprednisolone, and fully recovered after azathioprine was added, which suggests a significant role for large doses of steroids and immunosuppression in some cases. The cervical cord lesions in case 2 extended over more than three segments but did not appear to be contiguous; this is also seen in multiple sclerosis, but it has no such brain lesions.</p>
<p>The two cases show a new unusual non-infective cause of meningoencephalitis-like symptoms, suggesting that the differential diagnosis of meningoencephalitis should consider NMOSD. Characteristic MRI lesions and anti-AQP4 antibody are two effective factors to differentiate them from other etiologies. Recognition of the MRI lesions characteristic of NMOSD is particularly important to make a correct diagnosis, since this is the primary form of examination currently used in the clinic. And positive anti-AQP4 antibody testing can establish the final diagnosis.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Professor DM Wingerchuk (Mayo Clinic College of Medicine) for reviewing the materials of case 1 and authenticating our diagnosis before the optic neuritis attack, and Dr. IC Bruce (Zhejiang University School of Medicine) for reading the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding statement</label>
<p>JY Wang receives grants from the National Natural Science Foundation of China (81100877) and the Ph.D. Programs Foundation of the Ministry of Education of China (20113420120003).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512459785">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Krecke</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Brain abnormalities in neuromyelitis optica</article-title>. <source>Arch Neurol</source> <year>2006</year>; <volume>63</volume>: <fpage>390</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512459785">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waters</surname><given-names>PJ</given-names></name>
<name><surname>McKeon</surname><given-names>A</given-names></name>
<name><surname>Leite</surname><given-names>MI</given-names></name>
<etal/></person-group>. <article-title>Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>665</fpage>–<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512459785">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Lucchinetti</surname><given-names>CF</given-names></name>
<etal/></person-group>. <article-title>The spectrum of neuromyelitis optica</article-title>. <source>Lancet Neurol</source> <year>2007</year>; <volume>6</volume>: <fpage>805</fpage>–<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512459785">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ito</surname><given-names>S</given-names></name>
<name><surname>Mori</surname><given-names>M</given-names></name>
<name><surname>Makino</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>"Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>425</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512459785">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banker</surname><given-names>P</given-names></name>
<name><surname>Sonni</surname><given-names>S</given-names></name>
<name><surname>Kister</surname><given-names>I</given-names></name>
<etal/></person-group>. <article-title>Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>1050</fpage>–<lpage>1053</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512459785">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Kryzer</surname><given-names>TJ</given-names></name>
<etal/></person-group>. <article-title>A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>2106</fpage>–<lpage>2112</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512459785">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SH</given-names></name>
<name><surname>Kim</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>XF</given-names></name>
<etal/></person-group>. <article-title>Clinical spectrum of CNS aquaporin-4 autoimmunity</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>1179</fpage>–<lpage>1185</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512459785">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Downer</surname><given-names>JJ</given-names></name>
<name><surname>Leite</surname><given-names>MI</given-names></name>
<name><surname>Carter</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?</article-title> <source>Neuroradiology</source> <year>2012</year>; <volume>54</volume>: <fpage>279</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512459785">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W</given-names></name>
<name><surname>Park</surname><given-names>MS</given-names></name>
<name><surname>Lee</surname><given-names>SH</given-names></name>
<etal/></person-group>. <article-title>Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>1229</fpage>–<lpage>1236</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512459785">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W</given-names></name>
<name><surname>Kim</surname><given-names>SH</given-names></name>
<name><surname>Lee</surname><given-names>SH</given-names></name>
<etal/></person-group>. <article-title>Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1107</fpage>–<lpage>1111</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512459785">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>KH</given-names></name>
<name><surname>Tse</surname><given-names>CT</given-names></name>
<name><surname>Chung</surname><given-names>CP</given-names></name>
<etal/></person-group>. <article-title>Brain involvement in neuromyelitis optica spectrum disorders</article-title>. <source>Arch Neurol</source> <year>2011</year>; <volume>68</volume>: <fpage>1432</fpage>–<lpage>1439</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512459785">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname><given-names>D</given-names></name>
<name><surname>Fujihara</surname><given-names>K.</given-names></name>
</person-group> <article-title>Atypical presentations of neuromyelitis optica</article-title>. <source>Arq Neuropsiquiatr</source> <year>2011</year>; <volume>69</volume>: <fpage>824</fpage>–<lpage>828</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512459785">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sellner</surname><given-names>J</given-names></name>
<name><surname>Boggild</surname><given-names>M</given-names></name>
<name><surname>Clanet</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>EFNS guidelines on diagnosis and management of neuromyelitis optica</article-title>. <source>Eur J Neurol</source> <year>2010</year>; <volume>17</volume>: <fpage>1019</fpage>–<lpage>1032</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>